New Biomarker may Predict Alzheimer's Early

Early diagnosis of Alzheimer's disease may be possible with the discovery of a novel biomarker, according to a study published in the journal Neurology. The biomarker may be more accurate than the currently established biomarkers.

"Being able to identify who will develop Alzheimer's disease very early in the process will be crucial in the future," said study author Robert Perneczky, MD, of the Technical University Munich in Germany. "Once we have treatments that could prevent Alzheimer's disease, we could begin to treat very early and hopefully prevent the loss of memory and thinking skills that occurs with this devastating disease."

Alzheimer’s disease - Causes, Symptoms, Diagnosis, Stages, Types, Prevention, Prognosis & Treatment
Alzheimer's disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.

The study involved 58 people with slight memory problems, or mild cognitive impairment (MCI). Up to 15 percent of people with mild cognitive impairment develop Alzheimer's disease each year.

A sample of cerebrospinal fluid of the participants was taken at the beginning of the study through a lumbar puncture, or spinal tap. The concentrations in the cerebrospinal fluid of several proteins that are associated with Alzheimer's disease were measured.

The participants were followed for nearly three years on average. At that point, 21 people had developed Alzheimer's disease, 27 still had mild cognitive impairment and eight people had reverted back to their normal cognitive health. Two people had developed frontotemporal dementia, and their results were not included in the analysis.

Quiz On Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia. Participate in this quiz to find out how much you know about this debilitating disease.

Researchers found that the people who developed Alzheimer's disease had significantly higher levels of a protein called soluble amyloid precursor protein beta (sAPPÎ²) in their spinal fluid than those who did not develop Alzheimer's disease. Those who developed Alzheimer's disease had an average of 1,200 nanograms per milliliter, compared to 932 for those who did not develop the disease.

The researchers found that the best predictor of whether someone would develop Alzheimer's disease was a combination of sAPPÎ², the tau protein (an established marker of brain cell damage) and the age of the individual. When these factors were combined, the results were roughly 80 percent accurate in predicting whether the disease would develop.

Caring for Alzheimers disease patients
Alzheimer's disease is a complex brain disorder that triggers the most common form of dementia. The slide show will show how patients need support and care as dementia progresses.

The protein amyloid beta1-42, or AÎ²1-42, which has previously been considered a biomarker for Alzheimer's disease, was not a predictive factor in this study.

"These results suggest that sAPPÎ² as a biomarker may be useful and superior to the established marker AÎ²1-42 in the early diagnosis of Alzheimer's disease," Perneczky said.

Experts Say Alzheimer's may Cause Global Cash Crunch
A global cash crunch is possible in coming generations due to Alzheimer's disease - as people begin to live to 100, say experts.

"One possible explanation is that AÎ²1-42 measures events further downstream from the initial steps that lead to the production of the amyloid plaques that accumulate in the brains of people with Alzheimer's disease. sAPPÎ² is a measure of the first critical step in that process and may therefore provide more accurate information on the core pathological events."

Source-Eurekalert